News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
854,751 Results
Type
Article (87022)
Company Profile (704)
Press Release (767017)
Multimedia
Podcasts (154)
Webinars (20)
Section
Business (232894)
Career Advice (4133)
Deals (39769)
Drug Delivery (130)
Drug Development (91141)
Employer Resources (199)
FDA (18212)
Job Trends (17374)
News (396990)
Policy (39847)
Tag
Academia (3002)
Academic (2)
Accelerated approval (15)
Adcomms (33)
Allergies (110)
Alliances (56978)
ALS (123)
Alzheimer's disease (1616)
Antibody-drug conjugate (ADC) (192)
Approvals (18168)
Artificial intelligence (418)
Autoimmune disease (39)
Automation (22)
Bankruptcy (406)
Best Places to Work (12633)
BIOSECURE Act (22)
Biosimilars (139)
Biotechnology (482)
Bladder cancer (105)
Brain cancer (43)
Breast cancer (411)
Cancer (3248)
Cardiovascular disease (260)
Career advice (3542)
Career pathing (34)
CAR-T (217)
CDC (43)
Cell therapy (598)
Cervical cancer (25)
Clinical research (74535)
Collaboration (1165)
Company closure (3)
Compensation (762)
Complete response letters (42)
COVID-19 (2917)
CRISPR (71)
C-suite (404)
Cystic fibrosis (125)
Data (3303)
Decentralized trials (2)
Denatured (55)
Depression (83)
Diabetes (388)
Diagnostics (7002)
Digital health (26)
Diversity (10)
Diversity, equity & inclusion (49)
Drug discovery (194)
Drug pricing (160)
Drug shortages (36)
Duchenne muscular dystrophy (166)
Earnings (98085)
Editorial (50)
Employer branding (25)
Employer resources (169)
Events (131693)
Executive appointments (930)
FDA (20178)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (1047)
Gene editing (154)
Generative AI (42)
Gene therapy (466)
GLP-1 (957)
Government (5296)
Grass and pollen (7)
Guidances (281)
Healthcare (20921)
HIV (46)
Huntington's disease (32)
IgA nephropathy (46)
Immunology and inflammation (195)
Immuno-oncology (15)
Indications (43)
Infectious disease (3123)
Inflammatory bowel disease (168)
Inflation Reduction Act (13)
Influenza (80)
Intellectual property (131)
Interviews (813)
IPO (17907)
IRA (58)
Job creations (5194)
Job search strategy (2863)
Kidney cancer (15)
Labor market (62)
Layoffs (607)
Leadership (27)
Legal (10139)
Liver cancer (87)
Longevity (12)
Lung cancer (452)
Lymphoma (230)
Machine learning (14)
Management (65)
Manufacturing (487)
MASH (105)
Medical device (14760)
Medtech (14770)
Mergers & acquisitions (22625)
Metabolic disorders (991)
Multiple sclerosis (107)
NASH (23)
Neurodegenerative disease (165)
Neuropsychiatric disorders (47)
Neuroscience (2416)
NextGen: Class of 2025 (7687)
Non-profit (5091)
Now hiring (51)
Obesity (503)
Opinion (295)
Ovarian cancer (108)
Pain (131)
Pancreatic cancer (136)
Parkinson's disease (206)
Partnered (25)
Patents (343)
Patient recruitment (197)
Peanut (55)
People (65832)
Pharmaceutical (143)
Pharmacy benefit managers (25)
Phase I (22994)
Phase II (32366)
Phase III (24370)
Pipeline (1910)
Policy (259)
Postmarket research (3554)
Preclinical (10389)
Press Release (72)
Prostate cancer (157)
Psychedelics (46)
Radiopharmaceuticals (279)
Rare diseases (547)
Real estate (7402)
Recruiting (76)
Regulatory (27360)
Reports (62)
Research institute (2667)
Resumes & cover letters (650)
Rett syndrome (10)
RNA editing (12)
RSV (62)
Schizophrenia (106)
Series A (175)
Series B (124)
Service/supplier (30)
Sickle cell disease (69)
Special edition (22)
Spinal muscular atrophy (168)
Sponsored (38)
Startups (4309)
State (2)
Stomach cancer (17)
Supply chain (86)
Tariffs (74)
The Weekly (97)
Vaccines (949)
Venture capital (62)
Weight loss (341)
Women's health (52)
Worklife (20)
Date
Today (184)
Last 7 days (688)
Last 30 days (2336)
Last 365 days (33836)
2025 (20290)
2024 (38139)
2023 (42568)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1278)
Alabama (72)
Alaska (7)
Arizona (283)
Arkansas (14)
Asia (50621)
Australia (8895)
California (8166)
Canada (2506)
China (757)
Colorado (347)
Connecticut (363)
Delaware (218)
Europe (116202)
Florida (1218)
Georgia (277)
Hawaii (3)
Idaho (67)
Illinois (761)
India (34)
Indiana (404)
Iowa (19)
Japan (248)
Kansas (118)
Kentucky (34)
Louisiana (20)
Maine (73)
Maryland (1152)
Massachusetts (6251)
Michigan (281)
Minnesota (510)
Mississippi (4)
Missouri (107)
Montana (32)
Nebraska (26)
Nevada (87)
New Hampshire (74)
New Jersey (2277)
New Mexico (31)
New York (2258)
North Carolina (1281)
North Dakota (10)
Northern California (3563)
Ohio (263)
Oklahoma (17)
Oregon (48)
Pennsylvania (1744)
Puerto Rico (18)
Rhode Island (40)
South America (1654)
South Carolina (36)
South Dakota (1)
Southern California (3050)
Tennessee (134)
Texas (1259)
United States (30708)
Utah (240)
Virginia (223)
Washington D.C. (80)
Washington State (713)
West Virginia (4)
Wisconsin (89)
There are 854,751 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Earnings
Lilly Faces Triple Threat of Drug Pricing Pressure as CEO Emphasizes Value
From the price of forthcoming weight loss pill orforglipron, to Most Favored Nation drug pricing and the market battle with Novo Nordisk, pricing was the number one issue for Eli Lilly on its second quarter earnings call.
August 7, 2025
·
3 min read
·
Annalee Armstrong
Press Releases
Stem Cell Therapy Market Size to Hit USD 78.39 Billion by 2032, Growing at a CAGR of 22.8% from 2025 to 2032 | Coherent Market Insights
August 7, 2025
·
1 min read
Job Trends
Hiring Outlook: Latest Job, Application Numbers Highlight Tough Job Market
Higher competition for fewer roles remains the status quo for biopharma professionals, based on
BioSpace
data. Additionally, the U.S. Bureau of Labor Statistics has reported that recent job growth is lower than previously believed.
August 7, 2025
·
4 min read
·
Angela Gabriel
Cancer
Big Pharma-Backed mRNA Startup Bags $153M Series B Amid Policy Headwinds
Strand Therapeutics’ lead asset is STX-001, an intra-tumor self-replicating mRNA therapy that carries a payload expressing the immunomodulatory protein IL-12.
August 7, 2025
·
2 min read
·
Tristan Manalac
Obesity
UPDATE: Lilly’s Oral Weight Loss Drug Underdelivers, But Executives See Real World Opportunity
Eli Lilly’s orforglipron cut body weight to a lesser extent than rival Novo Nordisk’s semaglutide, falling into analysts’ bear scenario for the oral med. Executives brushed off the concerns and said the drug will still have a wide advantage on the market.
August 7, 2025
·
4 min read
·
Annalee Armstrong
Earnings
Despite Safety Drama, Sarepta Beats Q2 Estimates—But No Thanks to Elevidys Sales
Sarepta did not hold an investor call for its second-quarter earnings report or provide an updated full-year revenue outlook.
August 7, 2025
·
2 min read
·
Tristan Manalac
Layoff Tracker
60 Biotech Staff Lose Jobs as Poseida, Alltrna Reduce Workforce
Follow along as
BioSpace
tracks job cuts and restructuring initiatives throughout 2025.
August 7, 2025
·
177 min read
·
BioSpace Editorial Staff
Press Releases
Strand Therapeutics Raises $153 Million Series B Financing to Further Advance Programmable mRNA Therapeutic Pipeline
August 7, 2025
·
5 min read
IN PARTNERSHIP WITH CRESSET
From Chat Bots to World Order: The Race for the 21st Century’s Operating System
In this episode presented by Cresset, BioSpace’s head of insights Lori Ellis discusses the emerging geopolitical battle for AI supremacy and global AI governance with Mutlu Dogruel, VP of AI and Mark Mackey, CSO of Cresset.
August 7, 2025
·
1 min read
·
Lori Ellis
Press Releases
Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring Its Portfolio Value and Industry Leadership
August 7, 2025
·
7 min read
1 of 85,476
Next
